Treating the Untreatable
TARGETS
THE PROBLEM: Neuroinflammation
Neuroinflammation comprises a wide variety of immune responses that contribute significantly to chronic central nervous system disorders and brain cancers. Therapeutic use of brain penetrating Nrf2 activators against NLRP3 inflammasome activation may prevent inflammatory conditions. 2P-Im is a bi-functional small molecule that activates Nrf2 and interacts with the NLRP3 Inflammasome complex modulating its downstream signaling pathways.
Our LEAD: 2P-Im
2P-Im is an anti-inflammatory inhibitor of oxidative stress that targets cell networks and tumor microenvironments. It penetrates the blood-brain barrier and is toxic to tumor cells. It inhibits inflammasome activity and blocks essential mitochondrial Stress Response Proteins (SRPs) that fuel tumor growth. It targets tumor-induced immune suppression and helps overcome resistance. Its ability to synergize with the current neuro-oncology standards of care provides an opportunity for “fast track” FDA approval. 2P-Im is administered orally and has strong bioavailability.